MODIFICATION
B -- Metabolite Profiling for the Development of Diagnositc Biosensor for Malaria
- Notice Date
- 7/1/2013
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2013-59437
- Archive Date
- 7/25/2013
- Point of Contact
- Tayaria L Smith, Phone: 7704882797
- E-Mail Address
-
gqq4@cdc.gov
(gqq4@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice of Intent 2013-59437 The Centers of Disease Control and Prevention intends to award a sole source, firm fixed price contract, in accordance with FAR Part 13, using simplified acquisition procedures, to Emory University, Atlanta GA, 30322. Emory University will deliver the following: Performance Work Statement Metabolite Profiling for the Development of Diagnostic Biosensor for Malaria A. Background and Need The Malaria Branch at the US Centers for Disease Control and Prevention (CDC/MB) conducts surveillance, investigations, and studies of malaria to develop effective methods for the prevention, control, and elimination of disease worldwide. To that end, programs of epidemiologic and laboratory research investigating the biology, ecology, and host relationships of the malaria parasite have been established. In rural malarious areas, the currently available malaria diagnostic tools based on morphology, parasite antigen recognition, or DNA analysis of blood samples are limited to large-scale laboratories capable of expert microscopy or real-time molecular screening of asymptomatic and low density malaria. A primary aim of this collaborative project is to first determine the malaria parasite specific low-molecular-weight metabolites found in the urine and saliva of malaria infected humans. The ultimate goal is to provide proof of concept in the use of parasite-specific metabolites as biomarkers for the development of a sensitive, low-cost, simple and field-deployable urine and/or saliva diagnostic biosensor for detection of malaria infection. CDC provides substantial technical support to various malaria control programs globally and is a key partner in the President's Malaria Initiative (PMI), a vital component of the CDC priority to improve global health. Previous success in malaria controls has led to increased discussion about the medium- term feasibility of malaria elimination in selected areas, and in the long-term, malaria eradication. One of the critical elements in malaria elimination/eradication is large-scale and real-time screening of asymptomatic and low density malaria infection at the community level. Achieving prompt treatment will decrease the parasite reservoir and further reduce malaria transmission. Development of sensitive, low-cost, simple and field-deployable non-invasive diagnostic tools for malaria infection will have an enormous impact on monitoring the current PMI and future global malaria elimination programs. I. Background Current malaria diagnostic tools include: 1) parasite detection by microscopic examination of blood smears, 2) antigen-based rapid diagnostic tests (RDTs), and 3) sensitive DNA-based assays. All these diagnostic methods require blood sampling by finger-prick and their implementation has been limited by either their labor/time intensive nature and requirement of specific training (microscopic method), low sensitivity (RDTs), or high cost of sample preparation and supporting infrastructure needed (DNA-based methods). Although a few recent studies have reported a new non-invasive sampling of urine and saliva to detect malaria infection using the previously defined parasite antigens or DNA-based targets developed for existing methods, targeting such large molecules in urine and saliva has resulted in lower sensitivity compared to the same tests using blood samples. For malaria elimination efforts aiming to decrease the parasite reservoir to further transmission reduction, large-scale and real-time screening of asymptomatic, low density malaria infection using a sensitive, low-cost, simple and field-deployable non-invasive diagnostic tool at the community level (as opposed to clinical cases in hospitals) is increasingly important. This project addresses one of the monitoring and assessment challenges to successful implementation of the President's Malaria Initiative (PMI), which is one of the key components for the CDC strategic priority of improving global health. II. Project Description The period of performance shall be 10 months from the date of award. VI. Minimum Vendor Qualifications Qualifications of research team: Research team should have extensive biomedical research experience in the field of metabolomics and in the development of the high-resolution mass spectrometry methods. Specific experience in laboratory and non-human primate models for malaria and also other human research projects is necessary. Research team should be supported by analytic chemists with experience in high-resolution mass spectrometry and metabolomics analyses. An experienced bioinformatician is required for data extraction, biostatistical and bioinformatics analyses to support this project. Emory University appears to be the only organization that can provide this service. Their research team has extensive biomedical research experience in the field of metabolomics and in the development of the high- resolution mass spectrometry methods. They have specific experience in laboratory and non-human primate models for malaria and also other human research projects. There are supported by analytic chemists with experience in high-resolution mass and metabolomics analyses, as well as a bioinformatician for data extraction, bio statistical and bioinformatics analyses. The organization has the experience and technical expertise to collect and bacteriologically test scabies specimens from populations. This advertisement ends in 3 days accordance with FAR 5.203 (A) (1). No Request for Quotes (RFQ) will be issued based upon this Notice of Intent. Any interested companies are welcome to submit their credentials and ability to provide the services, via e-mail, gqq4@cdc.gov. Include reference number (2013-59437). Send responses by Wednesday July 3, 2013.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2013-59437/listing.html)
- Record
- SN03104498-W 20130703/130701234814-44607f50b7ea508948d35300fceccc91 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |